Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson’s disease

Mutations in LRRK2, a leading genetic cause of Parkinson's disease (PD), are linked to immune dysregulation, but the immune profiles in the periphery and central nervous system (CNS) remain incompletely defined. This study utilized a large cohort of serum samples (n = 651) and matched CSF samples (n = 129) from LRRK2 mutation carriers and non-carriers, with and without PD, to assess immune regulators using Luminex immunoassay. After correction for multiple comparisons, LRRK2 mutations were associated with significantly elevated serum levels of SDF-1 alpha and TNF-RII, while CSF markers such as BAFF, CD40L, and IL-27 were nominally reduced. Regardless of LRRK2 status, PD was associated with nominally lower levels of inflammatory analytes in CSF, with minimal changes observed in serum. Correlation analyses revealed distinct immune profiles between serum and CSF, suggesting compartmentalized immune responses. These findings highlight immune alterations in LRRK2 mutation carriers and PD, providing potential serum markers for monitoring immune responses and avenues for mechanistic studies.

Authors

Institutions

Publication Details

Journal
npj Parkinson s Disease
Published
2025-11-27
DOI
https://doi.org/10.1038/s41531-025-01215-5
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson’s disease

Hussein A. Tawbi, Xiqun Chen, Jackson G. Schumacher, Sarfraz Ahmed et al.
npj Parkinson s Disease
Parkinson's Disease Mechanisms and Treatments
article

Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson’s disease

Hussein A. Tawbi, Xiqun Chen, Jackson G. Schumacher, Sarfraz Ahmed, Michael A. Schwarzschild, Jian Wang, Jae Suk Ahn, Yukun Tan, Weiyi Peng, Roshni Jaffery, Jiayin Zhang, Ken Chen, Yuhang Zhao, Yujia Wang, L Shi
article en

Abstract

Mutations in LRRK2, a leading genetic cause of Parkinson's disease (PD), are linked to immune dysregulation, but the immune profiles in the periphery and central nervous system (CNS) remain incompletely defined. This study utilized a large cohort of serum samples (n = 651) and matched CSF samples (n = 129) from LRRK2 mutation carriers and non-carriers, with and without PD, to assess immune regulators using Luminex immunoassay. After correction for multiple comparisons, LRRK2 mutations were associated with significantly elevated serum levels of SDF-1 alpha and TNF-RII, while CSF markers such as BAFF, CD40L, and IL-27 were nominally reduced. Regardless of LRRK2 status, PD was associated with nominally lower levels of inflammatory analytes in CSF, with minimal changes observed in serum. Correlation analyses revealed distinct immune profiles between serum and CSF, suggesting compartmentalized immune responses. These findings highlight immune alterations in LRRK2 mutation carriers and PD, providing potential serum markers for monitoring immune responses and avenues for mechanistic studies.

npj Parkinson s DiseaseVol. 11(1)
The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Massachusetts General Hospital (US), Research Network (United States) (US), University of Houston (US)
Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health
Openalex Percentile: Top 49%
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.